Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Februar 2026 08:00 ET | Quelle: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Aardvark Therapeutics announced a Phase 3 HERO trial protocol amendment expanding eligibility for patients with Prader-Willi Syndrome.
05. Februar 2026 07:14 ET | Quelle: Research and Markets

Phenylketonuria (PKU) Global Clinical Trials Market Review 2025: G7 and E7 Activities, Trial Status, Sponsor Insights, Enrollment Trends, Company Listings, Unaccomplished Trials

Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Phenylketonuria (PKU) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
06. Januar 2026 09:13 ET | Quelle: Research and Markets

TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines

Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. ...
13. November 2025 05:00 ET | Quelle: ITM Isotope Technologies Munich SE

ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

ITM Announces FDA NDA Acceptance and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in GEP-NETs
25. Oktober 2025 03:00 ET | Quelle: ITM Isotope Technologies Munich SE

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade...
22. Mai 2025 09:41 ET | Quelle: Research and Markets

CD40 Targeted Therapies Market Research Report 2025: Clinical Trials, Therapeutic Approaches & Market Opportunities to 2027 - Competition Heats Up with 20+ Therapies in Advanced Stage

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025" has been added to ResearchAndMarkets.com's...
22. Mai 2025 07:45 ET | Quelle: Research and Markets

Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights 2024-2029: Innovations Rise with Over 60 Drugs in Clinical Trials, China Leads with Promising New Therapies

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029" has been added to ResearchAndMarkets.com's offering. Claudin18.2...
14. Mai 2025 07:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date...
06. Mai 2025 09:00 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the...
27. März 2025 08:56 ET | Quelle: Research and Markets

Insomnia Global Clinical Trials Review 2025, featuring Takeda Pharmaceutical, Merck, Idorsia, Johnson & Johnson, Eisai, Sanofi, Neurocrine Biosciences, Thermo Fisher Scientific, Neurim Pharmaceuticals

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Insomnia - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report...

Nächste Seite